Oura and MD Live Partner to Support GLP-1 Patients
Patients will soon share wearable biometric data with virtual doctors to help manage GLP-1 medication care.
Updated on Oct. 22, 2026 in Diabetes
Live Poll
Do you trust wearable health data to help improve your clinical care outcomes?
Oura and MD Live are partnering to integrate wearable health data with virtual primary care for patients using GLP-1 medications. Beginning in 2027, eligible members in employer-sponsored health plans will be able to share biometric and symptom tracking data with their clinicians.
Why it matters
This partnership aims to bridge the gap between doctor visits by helping patients monitor side effects and medication adherence in real time. Providing clinicians with continuous biometric data may assist in managing the long-term health needs of individuals on GLP-1 therapies.
Recent data shows 80% of Oura's 260,000 GLP-1 Insights users remain engaged with medication tracking three months after enrollment. While this suggests high user interest in biometric monitoring, the long-term clinical impact of sharing this data during telehealth visits is not yet known.
The players
Oura
A health technology company known for developing smart rings that track biometric data, sleep, and activity metrics.
MD Live
A national telehealth provider that offers virtual primary care services to patients through employer-sponsored health plans.
The details
The integration allows patients to use an Oura ring to track biometric metrics, medication intake, meals, and symptoms. This data is processed through the Oura Advisor AI tool and shared with MD Live clinicians, who use the information to inform virtual primary care consultations. The system is designed to provide doctors with a more comprehensive view of how a patient is responding to medication between scheduled appointments.
Timeline
March 2026: Oura launched the GLP-1 Insights feature.
October 2026: Oura and MD Live announced their new partnership.
2027: Eligible patients will gain access to smart rings and biometric analysis.
Health Landscape
The current telehealth landscape for GLP-1 prescriptions is highly fragmented, with only 26.5% of analyzed sites requiring video visits. This partnership aims to standardize the care process by incorporating objective biometric tracking into the virtual primary care experience.
If you are using GLP-1 medications, checking whether your employer-sponsored health plan includes MD Live coverage can help you prepare for these upcoming access features. You may want to discuss with your doctor whether tracking biometric data or side effects at home could help personalize your treatment plan.
The takeaway
Using wearables to monitor symptoms and medication habits can provide valuable data for your healthcare team. Always discuss any observations from your health tracking tools with your physician before making changes to your health regimen.
Further reading
Learn more about the latest research and management strategies in our Diabetes section.
Source note: This article includes information reported by TechTarget.
Live Poll
Do you trust wearable health data to help improve your clinical care outcomes?
